Live market screen
Commercial Space Company Risk / Opportunity Ranking
Opportunity/risk view across launch, satellites, SAR, earth observation, defense demand, financing events, and execution risk.
Updated June 27, 2026
Opportunity view
Showing rows 21-40 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 21 | GalaxEye mediummedium | Opp 7 Risk 4 | Thesis: GalaxEye has the clearest opportunity evidence in the screen because it moved from pre-launch to an actual in-orbit milestone for Mission Drishti, described as the first OptoSAR satellite, and also has evidence of a commercialization path via an NSIL data-resale arrangement. For a 1 year+ horizon, a successful first satellite launch can support follow-on constellation buildout, data sales, and fundraising progression if commissioning and execution continue. Why now: The key timing change is that earlier pre-launch coverage from April 23, 2026 was followed by launch coverage on May 3, 2026/May 4, 2026, and later June 16, 2026 context states the first satellite was launched in May 2026, confirming a business-state transition from concept/pre-launch to deployed asset status. The NSIL resale agreement was reported earlier on February 13, 2026, giving a potential go-to-market bridge once satellite data is available. Evidence
Caveats: Most reviewed sources rows are neutral facts or supporting article context rather than explicit positive evidence. Funding totals vary across articles (~$14.5M, $18.3M, ~$20M), so exact capitalization is uncertain |
| 22 | Loft Orbital mediummedium | Opp 7 Risk 3 | Thesis: Loft Orbital has the strongest opportunity case in this screen because multiple dated within the recent evidence window articles describe a multi-year CNES contract worth up to tens of millions of euros for a next-generation Earth observation constellation, with the first satellite scheduled for Q4 2026 or by year-end 2026. Additional 2026 context says Loft is expanding from hosted payloads into full-service 'constellations as a service,' which supports a durable 1 year+ strategic scaling thesis. Why now: Why now is credible for a 1 year+ horizon because several dated articles from 2026 establish a recent contract win and near-forward deployment timeline: Loft announced on April 30, 2026 a multi-year CNES contract worth up to tens of millions of euros with first satellite scheduled to launch in Q4 2026. Via Satellite on May 1, 2026 described a 10-satellite EO constellation under that contract. SpaceNews on May 5, 2026 said Loft is expanding into 'full-service constellation deals'. Evidence
Caveats: Most retained support is supporting article context, which the reviewed sources treats as bounded context and weaker than direct dated event/fact evidence. Several favorable funding articles for Loft are dated January 2025 and were dropped by the 90-day recent evidence window, so they should not drive the current score. Execution risk remains around deploying the constellation and meeting the stated 2026 launch timing. |
| 23 | Momentus mediummedium | Opp 7 Risk 5 | Thesis: Momentus has credible 1 year+ opportunity from recent execution milestones and commercial/government traction: Vigoride 7 launched in late March 2026, and in June 2026 the company announced a new commercial contract for Vigoride-9 in-orbit services. This supports product progression from demonstration toward revenue-bearing missions. Why now: Why-now is supported by recent mission and contract evidence within the recent evidence window: on March 30, 2026 Momentus announced the successful launch of Vigoride 7 and called it its most advanced on-orbit demonstration campaign to date; on June 17, 2026 it announced a new commercial contract with LASP to host and operate the OWLS mission on Vigoride-9, expanding its commercial revenue portfolio. Evidence
Caveats: The SHIELD contract-vehicle selection is dated December 10, 2025 and outside the 90-day recent evidence window, so it is useful background but not a recency catalyst here. Some weak context rows repeat the same article-level claims and are not independent confirmation. |
| 24 | Open Cosmos mediummedium | Opp 7 Risk 3 | Thesis: Open Cosmos has the clearest visible operating-progress evidence in the screen. A June 17, 2026 article says it launched the first two satellites of its new Ka-band LEO telecom constellation and had secured a license from Liechtenstein a week earlier to use high-priority radio bands, indicating actual network rollout and regulatory progress toward sovereign and secure communications offerings for governments and enterprises. Why now: The timing is favorable for a 1 year+ horizon because the latest dated evidence on June 17, 2026 indicates market entry and operation of the first telecom satellites, which can matter over a multi-quarter rollout period. A prior April 8, 2026 article also shows Open Cosmos spacecraft being used in the Orpheus UK military mission, adding defense-adjacent relevance. These dates are source dates extracted from the article summaries. Evidence
Caveats: Evidence is external article context and weak-context rows, not direct positive events. Same-article repeated rows are not independent confirmation. |
| 25 | Rocket Lab USA, Inc. highstrong | Opp 7 Risk 4 | Thesis: Rocket Lab has credible long-horizon opportunity from expanding beyond launch into higher-value national security satellite production and operations, while also showing continued commercial launch execution. Why now: The main catalyst is the May 2026 award of Rocket Lab's first GEO satellite production program for the U.S. Space Force, which extends the company into a new orbital regime and broadens its mission model. That is paired with evidence of ongoing launch execution on May 22, 2026 through the ninth dedicated Electron mission for Synspective. Evidence
Caveats: The reviewed sources contain no direct negative events, so risk is mainly execution-based rather than explicitly evidenced adverse news. One representative item references stock performance but is undated and should not be treated as reliable recency proof. |
| 26 | Sateliot mediummedium | Opp 7 Risk 5 | Thesis: Sateliot has a solid 1 year+ opportunity setup because company-linked facts say it launched a €100 million Series C round to deploy 16 satellites for 5G IoT and direct-to-device connectivity, while later article context adds that it signed its first commercial contract for a dedicated LEO launch for two Tritó satellites in 2027. The combination of financing and launch planning supports constellation build-out potential. Why now: The sequence matters: the company launched the Series C on April 8, 2026/April 13, 2026, then later reporting on May 21, 2026 noted a first commercial launch contract, and June 24, 2026 reporting still described the round as seeking capital and a lead investor. That mix creates both opportunity and financing risk over a 1 year+ horizon. Evidence
Caveats: The reviewed sources does not provide a direct positive event row for the first commercial contract; that support is supporting article context and weaker than a structured company event row. Later dated coverage indicates financing is still being sought, which partially offsets the opportunity thesis. Undated context items exist in the reviewed sources but are not used for recency-sensitive judgments. |
| 27 | SatSure mediummedium | Opp 7 Risk 4 | Thesis: SatSure has the strongest non-Boeing opportunity setup in this screen because multiple recent article summaries indicate it secured a 246 million rupee ($2.57 million) grant from India's space regulator to develop AI-powered Earth observation models, and a later June 2026 article says Safran Electronics & Defense and SatSure signed an MoU to collaborate on GEOINT solutions for the Indian market. Together these suggest both public-sector support and ecosystem partnership momentum relevant over a 1 year+ horizon Why now: Why now is strong because the June 11-22, 2026 evidence sequence shows fresh capital support first, then a later strategic partnership, suggesting opportunity maturation within weeks rather than stale background context Evidence
Caveats: Most evidence is supporting article context or weak context rather than direct positive events. Same-story repetition around the grant should not be treated as independent confirmation. No direct available evidence of revenue, backlog conversion, or deployment milestones. |
| 28 | Starfish Space mediumstrong | Opp 7 Risk 3 | Thesis: Starfish Space has the strongest positive evidence in the screen: recent Series B funding of more than $100 million and company-linked evidence of existing work with Space Force, NASA, and SES support a multi-year scaling thesis in on-orbit servicing. Why now: The timing is favorable for a 1 year+ horizon because recent financing on April 7, 2026 was explicitly tied to executing first servicing missions and boosting production, following prior government contract momentum Evidence
Caveats: The strongest support is external web-search evidence, though it is company-linked and dated. Some contract details in weaker article context vary and should not be over-aggregated across repeated articles. |
| 29 | TakeMe2Space mediummedium | Opp 7 Risk 3 | Thesis: TakeMe2Space has recent funding support from IN-SPACe under the Technology Adoption Fund, with the article stating selected startups will each receive up to ₹25 crore, which supports a durable financing-and-development opportunity over a 1 year+ horizon. Why now: The IN-SPACe funding article is dated June 12, 2026, very recent within the recent evidence window, and describes first investment into selected Indian spacetech startups including TakeMe2Space, which could shape the next year of development. Source date: June 12, 2026 Evidence
Caveats: Reviewed evidence notes prior broader membership support, but only one in-window article context is retained here. Evidence is supporting article context only despite stronger historical support counts. |
| 30 | Turion Space mediummedium | Opp 7 Risk 5 | Thesis: Turion Space has credible long-horizon opportunity because the reviewed sources show a sizable Series B closed on April 15, 2026 to accelerate deployment of its space domain awareness satellite fleet, alongside evidence that it has already launched spacecraft and is expanding a maneuverable satellite fleet for in-orbit observation missions. Why now: The key timing driver is the dated financing round on April 15, 2026, which the reviewed sources say positions the company to scale beyond single-mission spacecraft toward a persistent SDA constellation, a development relevant over a 1 year+ horizon. Evidence
Caveats: The reviewed sources have no direct positive or negative dated events; the case relies on supporting article context rather than stronger internal company-specific events. The company website context on May 23, 2026 is weaker than independent company-specific event evidence and should not be overweighted. Citation |
| 31 | Astrobase Space Technologies mediummedium | Opp 6 Risk 4 | Thesis: Astrobase has visible funding support tied to a specific propulsion-development goal. A June 12, 2026 article says IN-SPACe selected it under the Technology Adoption Fund and that each project can receive up to ₹25 crore; the same summary says Astrobase aims to develop a high-thrust closed-cycle liquid rocket engine. For a 1 year+ horizon, non-dilutive or quasi-public funding for propulsion development is a meaningful opportunity signal. Why now: The funding article is recent, with published June 12, 2026, and specifically notes this as IN-SPACe's first investment in Indian startups under the TAF scheme. That timing matters for a 1 year+ horizon because it may enable development progress over coming quarters. Evidence
Caveats: Visible evidence is only one external article summary despite the membership rationale referencing multiple structured support articles. No technical test results or customer contracts are provided in the exposed evidence. |
| 32 | Blue Origin mediummedium | Opp 6 Risk 7 | Thesis: Blue Origin has meaningful long-horizon upside from multiple recent demand signals: a Space Force national security launch task order, a planned return-to-service New Glenn launch for 48 Amazon Leo satellites, and a NASA moon-base award tied to a fall 2026 target window. Why now: The setup is active and recent: on May 30, 2026 SpaceNews reported Blue Origin received an NSSL task order hours before a New Glenn explosion, while on May 27, 2026 GeekWire reported New Glenn was preparing to return to service for an Amazon Leo mission after its first launch failure; on May 26, 2026 Investing.com summarized a NASA moon-base contract with launch no earlier than fall 2026 Evidence
Caveats: Positive evidence is mostly supporting article context rather than direct events. One external article is undated and is not relied on for recency proof. Government support after the anomaly partially offsets, but does not erase, execution risk. |
| 33 | ElevationSpace mediummedium | Opp 6 Risk 2 | Thesis: ElevationSpace has one of the better opportunity setups in this screen because the reviewed sources includes a recent dated article saying it raised $40 million in Series B funding, bringing total raised to $63.5 million, for a business developing space-to-Earth transportation and a space environment utilization and recovery platform. A large recent financing can support product development and scaling over a 1 year+ horizon. Why now: The catalyst is recent and dated: the financing article is timestamped June 19, 2026, which is inside the 90-day recent evidence window and recent enough to matter for a 1 year+ business-building horizon. Evidence
Caveats: Support is still supporting article context rather than direct positive events. Only one article is available, limiting corroboration. |
| 34 | General Atomics mediummedium | Opp 6 Risk 2 | Thesis: General Atomics has the clearest opportunity signal in the screen because an article dated April 8, 2026 says Space Systems Command awarded 14 companies more than $1.8 billion in Andromeda contracts for the Geosynchronous Reconnaissance & Surveillance Constellation, and General Atomics is named among the companies. For a 1 year+ horizon, inclusion in a large U.S. defense-space procurement could support durable program participation if it converts into funded work streams, though the reviewed sources only provides supporting article context rather than a direct company event row., April 8, 2026 Why now: The catalyst is recent within the reviewed sources recent evidence window: the is April 8, 2026, and it describes Space Force awarding Andromeda contracts, a potentially durable procurement cycle relevant to a 1 year+ horizon., April 8, 2026 Evidence
Caveats: This is supporting article context/weak context, not a direct company event row. Same-article repeated rows in the reviewed sources are not independent confirmation. |
| 35 | GITAI mediummedium | Opp 6 Risk 3 | Thesis: GITAI has the strongest opportunity setup in this screen because a dated June 16, 2026 company announcement says it completed the flight model of its S3 robotic satellite mission for an on-orbit servicing technology demonstration and framed the platform as supporting future defense-focused LEO constellation services, indicating tangible program maturation rather than just category membership. Why now: The key catalyst is recent and inside recent evidence window: on June 16, 2026, GITAI announced completion of the S3 flight model for an on-orbit servicing demonstration mission, which is directly relevant to a 1 year+ horizon because it may precede launch, demonstration, and downstream defense/commercial adoption over the next year. Evidence
Caveats: Primary evidence is from the company itself. No retained independent customer, contract, or revenue evidence is provided. The spaceindex.io entry is undated and should not be treated as recency proof. |
| 36 | Intuitive Machines, Inc. mediummedium | Opp 6 Risk 5 | Thesis: Intuitive Machines has moderate long-horizon opportunity because recent Space Force selection expands its relevance beyond lunar services into space surveillance capabilities, potentially broadening its addressable defense business. Why now: The timing case comes from May 12, 2026 reporting that Intuitive Machines was selected for the Space Force Andromeda IDIQ to develop space surveillance capabilities through 2030 and beyond, described as the company's first major selection following the Lanteris Space acquisition. Evidence
Caveats: The reviewed sources provide supporting article context but no direct structured fact with quantified contract value specific to Intuitive Machines. No direct adverse evidence is available; risk is based on competitive award structure and evidence limitations. Long-horizon upside depends on conversion from selection status into meaningful programs. |
| 37 | Kepler mediummedium | Opp 6 Risk 3 | Thesis: Kepler shows a meaningful operational milestone: the company said it successfully launched the first tranche of optical relay satellites and that a 10-satellite ring marks the beginning of its operational optical data relay network. For a 1 year+ horizon, first-network deployment can support follow-on service activation and adoption. Why now: The latest visible evidence is dated June 23, 2026, making the milestone recent within the 90-day recent evidence window. The article explicitly frames this as the beginning of an operational network, which is more relevant to a 1 year+ horizon than a short-lived announcement. Evidence
Caveats: Primary evidence is from Kepler's own site. No direct contract, revenue, or financing detail is provided in the visible evidence. Same article appears in both representative and weak-context forms, which is not independent confirmation. |
| 38 | L3Harris Technologies mediummedium | Opp 6 Risk 3 | Thesis: L3Harris has a moderate opportunity case from current participation in the Space Force’s Andromeda space domain awareness effort, which could support multi-year defense-space positioning. Recent article context published April 8, 2026 lists L3Harris among the companies awarded Andromeda contracts for RG-XX satellites. Why now: The recent timing anchor is the April 8, 2026 Andromeda article. Older 2020 MOSSAIC history exists in the reviewed sources but should not drive the current timing view because it is outside the recent evidence window and materially older than the current contract context. Evidence
Caveats: Current opportunity case depends on supporting article context rather than available direct positive events. The reviewed sources includes an older 2020 contract article, but that is not recent support for 'why now'. |
| 39 | Lockheed Martin mediummedium | Opp 6 Risk 2 | Thesis: Recent supporting article context indicates Lockheed Martin won a Space Force contract worth up to $105 million to modernize the GPS ground control network and support GPS IIIF operations, which supports a durable government-space revenue opportunity over a 1 year+ horizon. Why now: The relevant contract article is dated April 16, 2026, inside the 90-day recent evidence window, and describes current modernization work tied to GPS IIIF support, which can matter over a multi-quarter horizon. Source date: April 16, 2026 Evidence
Caveats: Evidence is supporting article context only; no direct positive event row is available. Same article appears in multiple weak-context rows and does not count as independent confirmation. |
| 40 | Logos Space Services mediummedium | Opp 6 Risk 4 | Thesis: Among this screen, Logos has the clearest in-recent evidence window strategic progress: it recently secured FCC approval for a very large broadband constellation of up to 4,178 satellites, which is a meaningful regulatory milestone for a long-horizon satellite communications buildout. Why now: A dated article within the 90-day recent evidence window, with based on April 13, 2026, states that Logos Space Services recently secured FCC approval for a constellation of up to 4,178 broadband satellites and described both target customers and technical architecture, making this a timely strategic-development signal for a 1 year+ horizon. Evidence
Caveats: Evidence is supporting article context, not a richer set of direct dated events/facts. Only one article after recent evidence window; same-article repeated rows are not independent confirmation. |
Risk view
Showing rows 421-438 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 421 | Apparition Geoservices GmbH lowweak | Opp 0 Risk 0 | Thesis: No negative thesis can be established because no direct negative evidence for Apparition Geoservices GmbH is available in the reviewed sources after recent evidence filtering. Why now: No current business-state change or catalyst is visible. Although 6 articles were considered, coverage debug shows 0 articles after recent evidence window and 0 evidence after recent evidence window, while the membership review says the reviewed sources are only a broad European tech funding roundup without a direct company-specific description. Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article Mention count and article count do not increase conviction because no post-recent evidence window evidence are available. Review-status rationale says retrieval context is insufficient for membership. |
| 422 | Arkeon lowweak | Opp 0 Risk 0 | Thesis: No negative thesis is supported because Arkeon has no direct negative evidence in the reviewed sources within the selected recent evidence window. Why now: No company-specific timing signal is visible. Coverage debug shows zero post-recent evidence window articles and evidence, and the membership note says only a generic funding-roundup article was available without a company-specific description tying Arkeon to the scope. Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article No direct event, fact, or negative development is available after recent evidence window. Low membership confidence is not directional evidence. |
| 423 | Ars Magna Semiconductors lowweak | Opp 0 Risk 0 | Thesis: No negative thesis can be formed because the reviewed sources includes no direct negative evidence for Ars Magna Semiconductors within the recent evidence window. Why now: There is no visible long-horizon strategic catalyst in the usable evidence. Coverage debug shows zero post-recent evidence window articles and evidence, and the only cited support is a general tech funding roundup without a company-specific description linking the company to the scope. Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article No direct positive or adverse operating evidence is available. Generic roundup context is weaker than company-specific evidence and is not directional proof. |
| 424 | Augusta Labs lowweak | Opp 0 Risk 0 | Thesis: No negative thesis is supportable because the reviewed sources have no direct negative evidence for Augusta Labs after recent evidence filtering. Why now: No current or durable catalyst can be identified from the reviewed sources. Coverage debug shows zero post-recent evidence window articles and evidence, and the membership note says the company is only present in a generic funding-roundup article without direct identification against the listed criteria. Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article Absence of risk evidence is not positive evidence. No direct company-specific facts or events are available. |
| 425 | BeatpulseLabs lowweak | Opp 0 Risk 0 | Thesis: No negative thesis can be justified because no direct negative evidence for BeatpulseLabs is present in the reviewed sources within the recent evidence window. Why now: There is no visible catalyst or deterioration signal. Coverage debug shows zero post-recent evidence window articles and evidence, and the only cited support is a generic funding-roundup article with no direct company-specific connection to the scope. Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article No direct event or fact evidence is available after recent evidence window. Generic context should not be treated as directional proof. |
| 426 | Bose Corporation lowweak | Opp 0 Risk 0 | Thesis: No negative/risk thesis can be supported because the reviewed sources contain no direct negative evidence for Bose Corporation after the 90-day recent evidence window. Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 97 articles considered but 0 articles after recent evidence window and 0 evidence available after dedupe; despite broad article consideration, nothing survived the time/evidence filters for a 1 year+ thesis judgment. Caveats: Phase-2 membership rationale says only a generic funding roundup was provided, tied to: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept. |
| 427 | Breaking Change lowweak | Opp 0 Risk 0 | Thesis: No negative/risk thesis can be supported because the reviewed sources contain no direct negative evidence for Breaking Change after the 90-day recent evidence window. Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 3 articles considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable. Caveats: Phase-2 membership rationale says the reviewed sources gives no meaningful company-specific evidence and references: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept. |
| 428 | CameraMatics lowweak | Opp 0 Risk 0 | Thesis: No negative thesis can be supported because there is no direct negative evidence for CameraMatics in the reviewed sources after recent evidence filtering. Why now: No company-specific catalyst is visible despite 6 articles considered, because coverage debug shows 0 articles after recent evidence window and 0 evidence after recent evidence window. The membership note says the reviewed sources only includes CameraMatics in a generic funding roundup with no direct statement tying it to the scope. Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article Article count does not create conviction because no post-recent evidence window evidence are available. No direct positive or adverse company-specific event is available. |
| 429 | Camphouse lowweak | Opp 0 Risk 0 | Thesis: No negative/risk thesis can be supported because the reviewed sources contain no direct negative evidence for Camphouse after the 90-day recent evidence window. Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 1 article considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable. Caveats: Phase-2 membership rationale says only a generic roundup mention was provided, tied to: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept. |
| 430 | Capsa AI lowweak | Opp 0 Risk 0 | Thesis: No negative/risk thesis can be supported because the reviewed sources contain no direct negative evidence for Capsa AI after the 90-day recent evidence window. Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 1 article considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable. Caveats: Phase-2 membership rationale says only a generic funding roundup was provided, tied to: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept. |
| 431 | CardNexus lowweak | Opp 0 Risk 0 | Thesis: No negative/risk thesis can be supported because the reviewed sources contain no direct negative evidence for CardNexus after the 90-day recent evidence window. Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 1 article considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable. Caveats: Phase-2 membership rationale says the reviewed sources does not provide direct company-specific evidence and references: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept. |
| 432 | CeQur lowweak | Opp 0 Risk 0 | Thesis: No negative/risk thesis can be supported because the reviewed sources contain no direct negative evidence for CeQur after the 90-day recent evidence window. Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 1 article considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable. Caveats: Phase-2 membership rationale says only a generic funding roundup was provided, tied to: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept. |
| 433 | EaglePicher Technologies lowweak | Opp 0 Risk 0 | Thesis: No negative thesis is supportable from retained reviewed sources evidence because no adverse events or facts are retained after recent evidence window. Why now: No current catalyst is evidenced in the retained reviewed sources. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window. Caveats: Phase-2 rationale references article, but the reviewed sources does not include the article summary or retained evidence. Supplier relevance to the space ecosystem does not by itself justify an opportunity score without current retained evidence. Recency is uncertain because the supporting substantive claims are not preserved in the recent evidence window evidence set. |
| 434 | IHI Corporation lowweak | Opp 0 Risk 0 | Thesis: No negative thesis is supportable from retained reviewed sources evidence because no adverse direct evidence remains after recent evidence window. Why now: There is no current why-now signal in the retained reviewed sources. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window. Caveats: Phase-2 rationale references article: but the actual retained evidence is absent from these reviewed sources. The rationale itself frames IHI more as a beneficiary/customer than clearly as the core space operator, which weakens directional use even if the older article were available. |
| 435 | OneWeb lowweak | Opp 0 Risk 0 | Thesis: No negative thesis is supportable from retained reviewed sources evidence because there are no direct negative evidence and no articles retained after the 90-day recent evidence window. Why now: There is no current why-now signal in the reviewed evidence. Coverage debug shows zero article IDs after recent evidence window and zero evidence after dedupe/recent evidence window. Caveats: Phase-2 rationale references article: but that article content is not provided here and no retained evidence remain after recent evidence window. Membership review status is not directional proof. Absence of evidence should not be interpreted as absence of business activity. |
| 436 | Starfighters Space Inc. lowweak | Opp 0 Risk 0 | Thesis: No negative thesis is supportable from retained reviewed sources evidence because no adverse evidence remains after the 90-day recent evidence window. Why now: No current why-now signal is available in the retained evidence. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window despite substantial historical article count. Caveats: Phase-2 rationale references articles: and: but their content is not included here. Historical mention density is not conviction. Public listing/ticker presence does not create a directional thesis without retained evidence. |
| 437 | Starlab Space lowweak | Opp 0 Risk 0 | Thesis: No negative thesis is supportable from retained reviewed sources evidence because no negative events or facts are retained after recent evidence window. Why now: No current why-now signal is available in the retained evidence. Coverage debug shows zero articles after recent evidence window and zero evidence after recent evidence window. Caveats: Phase-2 rationale references article: but the underlying article details are not included here. A referenced letter of intent, without retained evidence details or timing, is insufficient for a 1 year+ directional ranking. Private-company status may limit visibility, but that is not itself a thesis. |
| 438 | Zone14 lowweak | Opp 0 Risk 0 | Thesis: No negative thesis can be supported from the reviewed sources because there is no direct negative evidence available for Zone14 within the 90-day recent evidence window. Why now: There is no current company-specific catalyst visible in the reviewed sources. Coverage debug shows zero articles after recent evidence window and zero evidence after recent evidence window for Zone14; the membership note says it appears only through a broad funding roundup and lacks company-specific evidence tied to the listed scope. Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article Evidence recent evidence review shows 0 kept rows after the March 29, 2026 cutoff. Company appears only in review status with low membership confidence, which is not directional evidence. |